What worked at first stops working
As with many complicated conditions, there is a subset of methane SIBO clients who seem to thrive on prebiotics during and after treatment and those that become very symptomatic, something that is not yet well understood but will hopefully become clearer over time
It sounds almost too good to be true, doesn't it
Barriers That Still Exist Despite encouraging research, several obstacles remain: High monthly cost Limited coverage for weight loss alone Lengthy insurance appeals process Reluctance from employers and insurers to cover newer medications without long-term data Even when semaglutide is approved for coverage, patients often face prior authorization requirements , or their plans may only cover lower doses, certain brands, or specific medical indications
4 Complementary central nervous system action Amylin receptor signalling in the brain works through different neural circuits than GLP-1 receptor signalling
13 I believe that further research, including controlled studies and real-world evidence, will be essential to accurately assess the scope of cost savings and guide future policy decisions on GLP1 coverage and utilization
